EP Patent

EP4095130B1 — Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

Assigned to Novartis AG · Expires 2024-01-31 · 2y expired

What this patent protects

Patent listed against lutetium-lu-177-vipivotide-tetraxetan.

Drugs covered by this patent

Patent Metadata

Patent number
EP4095130B1
Jurisdiction
EP
Classification
—
Expires
2024-01-31
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.